105 related articles for article (PubMed ID: 16303791)
1. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin.
Nagashima F; Boku N; Ohtsu A; Yoshida S; Hasebe T; Ochiai A; Sakata Y; Saito H; Miyata Y; Hyodo I; Ando M
Jpn J Clin Oncol; 2005 Dec; 35(12):714-9. PubMed ID: 16303791
[TBL] [Abstract][Full Text] [Related]
2. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum.
Boku N; Chin K; Hosokawa K; Ohtsu A; Tajiri H; Yoshida S; Yamao T; Kondo H; Shirao K; Shimada Y; Saito D; Hasebe T; Mukai K; Seki S; Saito H; Johnston PG
Clin Cancer Res; 1998 Jun; 4(6):1469-74. PubMed ID: 9626464
[TBL] [Abstract][Full Text] [Related]
3. Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin.
Boku N; Ohtsu A; Yoshida S; Shirao K; Shimada Y; Hyodo I; Saito H; Miyata Y;
Jpn J Clin Oncol; 2007 Apr; 37(4):275-81. PubMed ID: 17522103
[TBL] [Abstract][Full Text] [Related]
4. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.
Tahara M; Ochiai A; Fujimoto J; Boku N; Yasui W; Ohtsu A; Tahara E; Yoshida S
Oncol Rep; 2004 Jan; 11(1):9-15. PubMed ID: 14654896
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma.
Takiuchi H; Hirata I; Kawabe S; Egashira Y; Katsu K
Oncol Rep; 2000; 7(4):841-6. PubMed ID: 10854555
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.
Fukuda H; Takiguchi N; Koda K; Oda K; Seike K; Miyazaki M
Cancer Invest; 2006; 24(3):235-41. PubMed ID: 16809149
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
[TBL] [Abstract][Full Text] [Related]
10. p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer.
Kikuyama S; Inada T; Shimizu K; Miyakita M; Ogata Y
Anticancer Res; 2001; 21(3C):2149-53. PubMed ID: 11501839
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Shah MA; Ramanathan RK; Ilson DH; Levnor A; D'Adamo D; O'Reilly E; Tse A; Trocola R; Schwartz L; Capanu M; Schwartz GK; Kelsen DP
J Clin Oncol; 2006 Nov; 24(33):5201-6. PubMed ID: 17114652
[TBL] [Abstract][Full Text] [Related]
12. p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer.
Nakata B; Chung KH; Ogawa M; Ogawa Y; Yanagawa K; Muguruma K; Inoue T; Yamashita Y; Onoda N; Maeda K; Sawada T; Sowa M
Surg Today; 1998; 28(6):595-8. PubMed ID: 9681607
[TBL] [Abstract][Full Text] [Related]
13. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.
Koizumi W; Kurihara M; Satoh A; Takiuchi H; Tanabe S; Shimada K; Iwasaki R; Saigenji K
Anticancer Res; 2005; 25(2B):1257-62. PubMed ID: 15865075
[TBL] [Abstract][Full Text] [Related]
14. Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy.
Hironaka S; Hasebe T; Kamijo T; Ohtsu A; Boku N; Yoshida S; Saitoh H; Ochiai A
Clin Cancer Res; 2002 Jan; 8(1):124-30. PubMed ID: 11801548
[TBL] [Abstract][Full Text] [Related]
15. Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP.
Boku N; Ohtsu A; Nagashima F; Shirao K; Koizumi W
Jpn J Clin Oncol; 2007 Jul; 37(7):509-14. PubMed ID: 17673469
[TBL] [Abstract][Full Text] [Related]
16. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy.
De Dosso S; Zanellato E; Nucifora M; Boldorini R; Sonzogni A; Biffi R; Fazio N; Bucci E; Beretta O; Crippa S; Saletti P; Frattini M
Cancer Chemother Pharmacol; 2013 Jul; 72(1):159-65. PubMed ID: 23645290
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice.
Yoshida M; Boku N; Ohtsu A; Muto M; Nagashima F; Yoshida S
Gastric Cancer; 2001; 4(3):144-9. PubMed ID: 11760080
[TBL] [Abstract][Full Text] [Related]
18. Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Bai M; Goussia A; Samantas E; Galani E; Tsavdaridis D; Karina M; Papakostas P; Konstantara A; Fountzilas G
Anticancer Res; 2007; 27(4C):2973-83. PubMed ID: 17695481
[TBL] [Abstract][Full Text] [Related]
19. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G
Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
